Amundi Has $2.55 Million Position in 10x Genomics $TXG

Key Points

• Amundi significantly increased its stake in 10x Genomics by 16,013.7% during Q1, now owning approximately 0.26%, valued at $2.55 million.
• Insider transactions indicated activity with CEO Serge Saxonov selling 9,348 shares and insider Benjamin J. Hindson selling 7,486 shares on the same day.
• 10x Genomics reported a quarterly earnings of $0.28 EPS, surpassing expectations, with revenue increasing 12.9% year-over-year to $172.91 million.

Amundi grew its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 16,013.7% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 320,340 shares of the company's stock after buying an additional 318,352 shares during the period. Amundi owned approximately 0.26% of 10x Genomics worth $2,553,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in 10x Genomics in the 4th quarter valued at approximately $32,000. GAMMA Investing LLC raised its holdings in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after acquiring an additional 1,614 shares in the last quarter. Signaturefd LLC raised its stake in shares of 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares in the last quarter. Whittier Trust Co. acquired a new position in shares of 10x Genomics in the first quarter valued at $41,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after purchasing an additional 3,119 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Trading Down 2.1%

Shares of 10x Genomics stock traded down $0.27 during mid-day trading on Wednesday, reaching $12.86. 2,265,462 shares of the stock were exchanged, compared to its average volume of 2,185,694. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -18.37 and a beta of 2.00. The firm has a 50-day simple moving average of $13.27 and a 200 day simple moving average of $10.86. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company's revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, research analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. UBS Group upped their target price on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Zacks Research cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 5th. Piper Sandler started coverage on shares of 10x Genomics in a research report on Thursday, September 11th. They issued a "neutral" rating and a $15.00 price target for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus price target of $13.65.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 in the last three months. Corporate insiders own 9.39% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.